Susquehanna International Group’s Akebia Therapeutics AKBA Stock Holding History

Susquehanna International Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$274K	Buy	197,300 +132,000	+202%	+$181K	﹤0.01%	11068
2025 Q4	$105K	Sell	65,300 -55,300	-46%	-$116K	﹤0.01%	11423
2025 Q3	$329K	Buy	120,600 +59,500	+97%	+$198K	﹤0.01%	9902
2025 Q2	$222K	Buy	61,100 +11,200	+22%	+$30.8K	﹤0.01%	10991
2025 Q1	$95.8K	Buy	+49,900	New	+$102K	﹤0.01%	11567
2024 Q4	–	Sell	-98,900	Closed	-$131K	–	12102
2024 Q3	$131K	Sell	98,900 -332,700	-77%	-$444K	﹤0.01%	10864
2024 Q2	$440K	Sell	431,600 -263,600	-38%	-$326K	﹤0.01%	8580
2024 Q1	$1.27M	Buy	695,200 +544,000	+360%	+$870K	﹤0.01%	6331
2023 Q4	$187K	Buy	151,200 +1,300	+0.9%	+$1.33K	﹤0.01%	10747
2023 Q3	$171K	Buy	149,900 +27,400	+22%	+$35.2K	﹤0.01%	10404
2023 Q2	$113K	Sell	122,500 -12,000	-9%	-$11.6K	﹤0.01%	10866
2023 Q1	$75.3K	Buy	134,500 +72,600	+117%	+$55.5K	﹤0.01%	11481
2022 Q4	$35.9K	Sell	61,900 -20,500	-25%	-$6.42K	﹤0.01%	11562
2022 Q3	$26K	Sell	82,400 -8,900	-10%	-$3.49K	﹤0.01%	12503
2022 Q2	$32K	Sell	91,300 -228,200	-71%	-$95.8K	﹤0.01%	12186
2022 Q1	$230K	Buy	319,500 +265,000	+486%	+$567K	﹤0.01%	10902
2021 Q4	$123K	Sell	54,500 -75,300	-58%	-$205K	﹤0.01%	11984
2021 Q3	$374K	Sell	129,800 -102,900	-44%	-$294K	﹤0.01%	10083
2021 Q2	$882K	Buy	232,700 +42,600	+22%	+$143K	﹤0.01%	8111
2021 Q1	$643K	Buy	190,100 +31,300	+20%	+$113K	﹤0.01%	8885
2020 Q4	$445K	Sell	158,800 -235,200	-60%	-$687K	﹤0.01%	8530
2020 Q3	$989K	Sell	394,000 -130,800	-25%	-$1.15M	﹤0.01%	6146
2020 Q2	$7.13M	Buy	524,800 +337,000	+179%	+$3.49M	﹤0.01%	2555
2020 Q1	$1.42M	Buy	187,800 +125,600	+202%	+$977K	﹤0.01%	4593
2019 Q4	$393K	Sell	62,200 -17,800	-22%	-$84.6K	﹤0.01%	7461
2019 Q3	$314K	Sell	80,000 -25,300	-24%	-$108K	﹤0.01%	8200
2019 Q2	$510K	Sell	105,300 -114,500	-52%	-$651K	﹤0.01%	7221
2019 Q1	$1.8M	Sell	219,800 -8,000	-4%	-$54.9K	﹤0.01%	3920
2018 Q4	$1.26M	Buy	227,800 +184,400	+425%	+$1.44M	﹤0.01%	4265
2018 Q3	$383K	Buy	43,400 +19,700	+83%	+$176K	﹤0.01%	6994
2018 Q2	$237K	Buy	+23,700	New	+$237K	﹤0.01%	8289
2017 Q4	–	Sell	-19,900	Closed	-$391K	–	9169
2017 Q3	$391K	Sell	19,900 -36,700	-65%	-$564K	﹤0.01%	6955
2017 Q2	$813K	Sell	56,600 -4,800	-8%	-$60.8K	﹤0.01%	5698
2017 Q1	$565K	Sell	61,400 -17,400	-22%	-$170K	﹤0.01%	6270
2016 Q4	$820K	Sell	78,800 -45,900	-37%	-$395K	﹤0.01%	5949
2016 Q3	$1.13M	Buy	124,700 +17,600	+16%	+$150K	﹤0.01%	4580
2016 Q2	$801K	Buy	107,100 +32,800	+44%	+$286K	﹤0.01%	5291
2016 Q1	$669K	Sell	74,300 -14,200	-16%	-$115K	﹤0.01%	5878
2015 Q4	$1.14M	Sell	88,500 -4,500	-5%	-$45.9K	﹤0.01%	5142
2015 Q3	$898K	Buy	93,000 +8,000	+9%	+$73.4K	﹤0.01%	5983
2015 Q2	$875K	Buy	85,000 +59,400	+232%	+$507K	﹤0.01%	6491
2015 Q1	$284K	Sell	25,600 -4,900	-16%	-$52.2K	﹤0.01%	8060
2014 Q4	$355K	Sell	30,500 -51,500	-63%	-$738K	﹤0.01%	7849
2014 Q3	$1.81M	Buy	+82,000	New	+$1.88M	﹤0.01%	4780

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Susquehanna International Group's AKBA Position: Q1 2026 in Review

Susquehanna International Group increased its Akebia Therapeutics (AKBA) stake by 11% in Q1 2026, buying an estimated $102K and bringing the position to 722,119 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #7874.

Susquehanna International Group first reported a position in AKBA in Q2 2014 and has held it in 40 quarters since. The position peaked at $4.01M in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Susquehanna International Group held 722,119 shares of Akebia Therapeutics worth $1M as of Q1 2026.
Susquehanna International Group bought 74,406 Akebia Therapeutics shares in Q1 2026, an estimated $102K.
Akebia Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7874 holding.
Susquehanna International Group first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 40 quarters since.
Susquehanna International Group's Akebia Therapeutics position peaked at $4.01M in Q1 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.